Is label-free LC-MS/MS ready for biomarker discovery?

Research output: Contribution to journalDebate/Note/Editorial

Standard

Is label-free LC-MS/MS ready for biomarker discovery? / Sandin, Marianne; Chawade, Aakash; Levander, Fredrik.

In: Proteomics Clinical Applications, Vol. 9, No. 3-4, 2015, p. 289-294.

Research output: Contribution to journalDebate/Note/Editorial

Harvard

APA

CBE

MLA

Vancouver

Author

Sandin, Marianne ; Chawade, Aakash ; Levander, Fredrik. / Is label-free LC-MS/MS ready for biomarker discovery?. In: Proteomics Clinical Applications. 2015 ; Vol. 9, No. 3-4. pp. 289-294.

RIS

TY - JOUR

T1 - Is label-free LC-MS/MS ready for biomarker discovery?

AU - Sandin, Marianne

AU - Chawade, Aakash

AU - Levander, Fredrik

PY - 2015

Y1 - 2015

N2 - Label-free LC-MS methods are attractive for high-throughput quantitative proteomics, as the sample processing is straightforward and can be scaled to a large number of samples. Label-free methods therefore facilitate biomarker discovery in studies involving dozens of clinical samples. However, despite the increased popularity of label-free workflows, there is a hesitance in the research community to use it in clinical proteomics studies. Therefore, we here discuss pros and cons of label free LC-MS/MS for biomarker discovery, and delineate the main prerequisites for its successful employment. Furthermore, we cite studies where label-free LC-MS/MS was successfully used to identify novel biomarkers, and foresee an increased acceptance of label-free techniques by the proteomics community in the near future. This article is protected by copyright. All rights reserved.

AB - Label-free LC-MS methods are attractive for high-throughput quantitative proteomics, as the sample processing is straightforward and can be scaled to a large number of samples. Label-free methods therefore facilitate biomarker discovery in studies involving dozens of clinical samples. However, despite the increased popularity of label-free workflows, there is a hesitance in the research community to use it in clinical proteomics studies. Therefore, we here discuss pros and cons of label free LC-MS/MS for biomarker discovery, and delineate the main prerequisites for its successful employment. Furthermore, we cite studies where label-free LC-MS/MS was successfully used to identify novel biomarkers, and foresee an increased acceptance of label-free techniques by the proteomics community in the near future. This article is protected by copyright. All rights reserved.

U2 - 10.1002/prca.201400202

DO - 10.1002/prca.201400202

M3 - Debate/Note/Editorial

VL - 9

SP - 289

EP - 294

JO - Proteomics Clinical Applications

T2 - Proteomics Clinical Applications

JF - Proteomics Clinical Applications

SN - 1862-8354

IS - 3-4

ER -